Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

Mostrar otras versiones (2)

Background:COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Among patients with hematologic malignancies, seroconversion rates also appear to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiedmeier, Julia E., Iqbal, Madiha, Munoz, Javier, Bezerra, Evandro D., Garcia Robledo, Juan Esteban, Bansal, Radhika, Johnston, Patrick B., Hathcock, Matthew, Larsen, Jeremy T., Bergsagel, P. Leif, Wang, Yucai, Reeder, Craig B., Leis, Jose F., Fonseca, Rafael, Palmer, Jeanne M., Warsame, Rahma M, Kourelis, Taxiarchis, Hayman, Suzanne R., Dingli, David, Kapoor, Prashant, Kumar, Shaji, Durani, Urshila, Villasboas, Jose C., Paludo, Jonas, Bennani, N. Nora, Ansell, Stephen M., Castro, Januario E, Kharfan-Dabaja, Mohamed A., Lin, Yi, Vergidis, Paschalis, Murthy, Hemant S., Rosenthal, Allison C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
704.Cellular Immunotherapies: Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701676/
http://dx.doi.org/10.1182/blood-2021-151859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701676/
http://dx.doi.org/10.1182/blood-2021-151859

Ejemplares similares